Cogent Biosciences, INC 10-Q quarterly reports

Cogent Biosciences reports a wider net loss in Q1 2026 due to increased R&D spending, but maintains a strong cash position and advances its pipeline.

Cogent Biosciences announced positive top-line results for bezuclastinib in Non-AdvSM, received Breakthrough Therapy Designation, and advanced multiple pipeline programs while extending its cash runway into 2027.

Cogent Biosciences reports positive clinical data for bezuclastinib in Non-Advanced Systemic Mastocytosis and secures significant new financing to extend its cash runway into 2027.

Cogent Biosciences reports a net loss for Q1 2025 and provides updates on its clinical programs, including expected top-line results and NDA submission plans.

Cogent Biosciences reported its third quarter 2024 financial results, highlighting progress in clinical trials and research programs.

Cogent Biosciences reported a net loss of $117.3 million for the first half of 2024, while highlighting progress in its clinical trials for bezuclastinib and other research programs.

Cogent Biosciences reported a net loss of $58.3 million for the first quarter of 2024, while highlighting progress in its clinical programs and research pipeline.